TotalMarketCap

Climb Bio

CLYMNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$510.034 M

$8.88 -4.82%

Close of 6 Nov 2026

As of 6 Nov 2026, Climb Bio (CLYM) has a market capitalization of $510.0M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$59.9M

Loss-making

Shares outstanding

58,738,178

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #183Aclaris TherapeuticsACRS$529.9M
  2. #184NeurogeneNGNE$516.1M
  3. #185Climb BioCLYM$510.0M
  4. #186Faeth TherapeuticsFTH$509.9M
  5. #187Puma BiotechnologyPBYI$505.4M

What if Climb Bio were worth as much as…

Open the what-if tool →

Gold $28.2T

$491,621.08

Per share 55,363× higher

Bitcoin $1.53T

$26,600.76

Per share 2,996× higher

Apple $5.02T

$87,327.81

Per share 9,834× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Climb Bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.